Sign in
Active, not recruitingNo phase

Effectiveness and Safety of Intra-articular SEMICAL GEL-B CROSS Therapy in Knee Osteoarthritis (SEM-ART1)

Key facts

Who runs it
Semikal Technology
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
102 people, planned
Started
15 Jan 2025
Ended
31 Jan 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cross-linked intra-articular hyaluronic acid
  • Placebo
Record updated
21 August 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (5)Hide the full registry criteria

Who can take part

  • Adults aged 18 and over, both male and female
  • Diagnosed with clinical knee osteoarthritis according to the American College of
  • Rheumatology (ACR) criteria, with Kellgren \& Lawrence stage II and III osteoarthritic findings on antero-posterior knee radiographs
  • Able to provide written informed consent

Who cannot take part

  • -

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate the effectiveness and safety of intra-articular injection of a cross-linked sodium hyaluronate; SEMICAL GEL-B CROSS, in knee osteoarthritis.

Read full original descriptionShow less

Primary objectives: The aim of this study is to obtain short- and long-term clinical data on the performance and safety of intra-articular injection of SEMICAL GEL B-CROSS, produced and marketed by Semical Biosurgery incorporated company, in knee osteoarthritis patients.

It is also aimed to monitoring known adverse events and complications, detecting previously unknown adverse events and complications, to identify and analyze emerging risks based on real-life data. Participants will receive intra-articular injection of either a cross-linked sodium hyaluronate (SEMICAL GEL-B CROSS); or placebo (isotonic saline solution) at baseline, and will be followed-up for one year to compare the effectiveness and safety of the given therapy.

The 2 groups in the trial

  • Cross-linked intra-articular hyaluronic acidExisting treatment, for comparison

    Cross-linked intra-articular hyaluronic acid (90 mg 3 ml cross-linked hyaluronic acid)

  • PlaceboPlacebo, for comparison

    Intra-articular isotonic saline solution (3 ml 0.9% isotonic saline) at the same dose as the treatment arm

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Effectiveness of Intra-articular Injection of a Cross-linked Sodium Hyaluronate in Knee Osteoarthritis: A Randomized, Prospective, Double-blind, Placebo-controlled, Cross-over, Post-marketing Clinical Follow-up Study
Publications
Record updated
21 August 2025